Drug Trial Radar · NCT04628936
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Nov 4, 2020
Primary completion
Mar 10, 2023
Study completion Jun 12, 2023
Sponsor
- Lead sponsor
- Kezar Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM) who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.
Conditions
- Polymyositis
- Dermatomyositis
Interventions
KZR-616Drug
Subcutaneous 30 mg for 1 week, then 45 mg weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Total Improvement Score (TIS) at OLE Week 48Time frame: 48 weeks
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
KZR Research Site
Beverly Hills, California
KZR Research Site
Orange, California
KZR Research Site
Miami, Florida
KZR Research Site
Kansas City, Kansas
KZR Research Site
Baltimore, Maryland
KZR Research Site
Ann Arbor, Michigan
KZR Research Site
Duncansville, Pennsylvania
KZR Research Site
Pittsburgh, Pennsylvania
KZR Research Site
Austin, Texas
KZR Research Site
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.